Success Stories: Collaborations With Big Pharma

29 September 2010 Past Event

Collaborations with big biotech and big pharma are on the rise as innovators forge ahead in a challenging economic environment. This growing trend demands creativity and diligent focus on the structure of these agreements to maximize their corporate and product development potential. Panelists will address the following issues and provide case studies that demonstrate how to ensure a successful collaboration:

  • Unique arrangement structures at specific product life cycle stages
  • Protecting IP
  • Avoiding short-term fallout
  • The impact of collaboration on future growth and exit strategies
  • Strategies from both sides of the agreement: increasing the opportunity for future collaborations


  • Richard A. Kaufman, Partner, Foley & Lardner LLP
  • Richard Bork, Corporate Patent Counsel, Novo Nordisk
  • Tim Opler, Ph.D., Principal, Torreya Partners
  • Thomas Beetham, Senior Corporate Counsel, Genzyme
  • Michael Lytton, Executive Vice President, Corporate and Business Development, Biogen Idec


Bad Holiday Season News! Estimates of an increase of Cyberattacks 20%!
13 December 2019
Internet, IT & e-Discovery Blog
Driving the Future of Automotive Technology
12 December 2019
Manufacturing Industry Advisor
Massachusetts Governor Proposes Facility Fee Ban
12 December 2019
Health Care Law Today
American Rule Prevails; PTO May Not Collect In-House Attorneys' Fees as "Expenses"
12 December 2019
IP Litigation Current
ACCC 46th Annual Meeting & Cancer Center Business Summit
04-05 March 2020
Washington, D.C.
Foley/Deloitte Compliance and Privacy Officer Roundtable
27 February 2020
Boston, MA
Let’s Talk Compliance
24 January 2020
Orlando, FL
New England Alliance Annual Meeting
15-17 January 2020
Woodstock, VT